HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.

  title={HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.},
  author={Frank Alexis and Pamela Basto and Etgar Levy-Nissenbaum and Aleksandar F. Radovic-Moreno and Liangfang Zhang and Eric M. Pridgen and Andrew Z Wang and Shawn L Marein and Katrina Westerhof and Linda K. Molnar and Omid C Farokhzad},
  volume={3 12},
  • Frank Alexis, Pamela Basto, +8 authors Omid C Farokhzad
  • Published 2008 in ChemMedChem
  • DOI:10.1002/cmdc.200800122
Affibodies are a class of polypeptide ligands that are potential candidates for cellor tissuespecific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). Here we report the development of drug delivery vehicles comprised of polymeric NPs that are surface modified with Affibody ligands that bind to the extracellular domain of the trans-membrane human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells which over express the HER-2 antigen. NPs… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.
Showing 1-10 of 36 extracted citations


Publications referenced by this paper.
Showing 1-8 of 8 references

$w aerm ar-text $w aerm ar-text $w aerm ar-text

  • A Orlova, M Magnusson, +8 authors FY. Nilsson
  • Cancer research
  • 2006
Highly Influential
3 Excerpts

Urologic oncology

  • F Alexis, JW Rhee, JP Richie, AF Radovic-Moreno, R Langer, OC. Farokhzad
  • 2008
1 Excerpt

Nanomedicine (London, England)

  • EM Pridgen, R Langer, OC. Farokhzad
  • 2007
1 Excerpt

British journal of cancer

  • KJ O'Byrne, AL Thomas, +4 authors WP. Steward
  • 2002
1 Excerpt

Science (New York, N.Y

  • R. Langer
  • 2001
1 Excerpt

Annual review of cell and developmental biology

  • E. Ruoslahti
  • 1996
2 Excerpts

Critical reviews in therapeutic drug carrier systems

  • MV Pimm
  • [PubMed:
  • 1988
1 Excerpt

Similar Papers

Loading similar papers…